{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T18:13:44Z","timestamp":1768587224993,"version":"3.49.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"41","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,13]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Pure squamous cell carcinoma (SCC) of the gallbladder is a rare malignant biliary tract tumor predominantly found in the body and neck of the gallbladder. However, its occurrence in the cystic duct is even rarer. Given its rarity, no established guidelines or consensus currently exist regarding the treatment of pure SCC of the gallbladder. We report an unusual case of SCC originating from the cystic duct with the intent of providing insights into the therapeutic approach for this type of malignancy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A male patient presented to our hospital with acute cholecystitis. Unexpectedly, imaging revealed gallbladder malignancy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Pathologic examination after surgery confirmed SCC of the cystic duct.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Despite elevated bilirubin levels, we were able to exclude hilar involvement, enabling radical tumor resection. Intraoperatively, we discovered that the tumor was located in the cystic duct, a site associated with a high likelihood of invasion into neighboring organs. The tumor demonstrated a predominantly exophytic growth pattern, which prompted us to refrain from extending the resection range, thereby striking a balance between complete tumor removal and surgical trauma. We performed liver wedge resection only to ensure a negative resection margin while preserving the anatomical structure to the greatest extent possible. Postoperative recovery was rapid and uncomplicated. Pathological examination confirmed pure SCC, which led us to initiate a regimen of nab-paclitaxel and cisplatin, which is known to be effective in other organ SCCs. Remarkably, the patient experienced a rare and severe posttreatment cardiovascular event. Consequently, we switched the patient to a chemotherapy regimen of gemcitabine and cisplatin, which ultimately yielded positive clinical outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>no evidence of tumor recurrence was observed within 1 year after surgery.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>The diagnosis and therapeutic strategy for rare tumors such as gallbladder SCC should be meticulously tailored based on their unique characteristics to optimize postoperative patient outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000035430","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T21:05:46Z","timestamp":1697231146000},"page":"e35430","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Squamous cell carcinoma of the cystic duct: A case report and literature review"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0032-406X","authenticated-orcid":false,"given":"Hui-Jun","family":"Wang","sequence":"first","affiliation":[{"name":"Department of General Surgery, Hohhot First Hospital, Hohhot, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Jie","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Hohhot First Hospital, Hohhot, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-Fang","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hohhot First Hospital, Hohhot, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Na","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hohhot First Hospital, Hohhot, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hohhot First Hospital, Hohhot, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Hua","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Hohhot First Hospital, Hohhot, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Hohhot First Hospital, Hohhot, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","DOI":"10.1002\/jso.26066","article-title":"Gallbladder squamous cell carcinoma: an analysis of 1084 cases from the National Cancer Database.","author":"Ayabe","year":"2020","journal-title":"J Surg Oncol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"E91","DOI":"10.1111\/ans.16452","article-title":"Characteristics and survival prognosis of patients with pure squamous cell carcinoma of the gallbladder.","volume":"91","author":"Zhu","year":"2021","journal-title":"ANZ J Surg"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"e0198809","DOI":"10.1371\/journal.pone.0198809","article-title":"Clinicopathological characteristics and outcomes of rare histologic subtypes of gallbladder cancer over two decades: a population-based study.","volume":"13","author":"Samuel","year":"2018","journal-title":"PLoS One"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.amjsurg.2020.06.050","article-title":"Adeno-squamous and squamous cell carcinoma of the gallbladder: the importance of histology in surgical management.","volume":"220","author":"Leigh","year":"2020","journal-title":"Am J Surg"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.amjsurg.2012.12.012","article-title":"Squamous variant of gallbladder cancer: is it different from adenocarcinoma.","volume":"206","author":"Kalayarasan","year":"2013","journal-title":"Am J Surg"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/jso.21813","article-title":"Clinicopathologic analysis of adenosquamous\/squamous cell carcinoma of the gallbladder.","volume":"103","author":"Kim","year":"2011","journal-title":"J Surg Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/jso.25781","article-title":"Clinicopathological features and survival outcomes of rare histologic variants of gallbladder cancer.","volume":"121","author":"Akce","year":"2020","journal-title":"J Surg Oncol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/jso.24065","article-title":"Squamous\/adenosquamous carcinoma of the gallbladder: analysis of 34 cases and comparison of clinicopathologic features and surgical outcomes with adenocarcinoma.","volume":"112","author":"Song","year":"2015","journal-title":"J Surg Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.surg.2021.01.045","article-title":"Optimal surgical management for T2 gallbladder cancer-formal 4b-5 resection.","volume":"169","author":"Serrablo","year":"2021","journal-title":"Surgery"},{"key":"R10-20250504","first-page":"243","article-title":"[Guideline for the diagnosis and treatment of gallbladder carcinoma (2019 edition)].","volume":"58","year":"2020","journal-title":"Zhonghua Wai Ke Za Zhi"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1245\/s10434-008-0189-3","article-title":"Analysis of the extent of resection for adenocarcinoma of the gallbladder.","volume":"16","author":"D\u2019Angelica","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer.","volume":"105","author":"Ebata","year":"2018","journal-title":"Br J Surg"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study.","volume":"37","author":"Edeline","year":"2019","journal-title":"J Clin Oncol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1007\/s00268-020-05656-2","article-title":"Clinicopathological characteristics and surgical outcomes of primary cystic duct carcinoma: a multi-institutional study.","volume":"44","author":"Sakata","year":"2020","journal-title":"World J Surg"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/MEG.0000000000000074","article-title":"Gallbladder cancers: associated conditions, histological types, prognosis, and prevention.","volume":"26","author":"Cariati","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"647","DOI":"10.21037\/tlcr-22-252","article-title":"The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung squamous cell carcinoma: a real-world retrospective cohort study.","volume":"11","author":"Jiang","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.2147\/CMAR.S298360","article-title":"Encouraging pathological complete response rate from neoadjuvant chemotherapy with albumin-bound paclitaxel plus cisplatin and capecitabine for locally advanced esophageal squamous carcinoma: preliminary outcome of a retrospective study.","volume":"13","author":"Zhang","year":"2021","journal-title":"Cancer Manag Res"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.2147\/OTT.S108580","article-title":"Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma.","volume":"9","author":"Wang","year":"2016","journal-title":"Onco Targets Ther"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cllc.2020.09.007","article-title":"Nanoparticle albumin-bound paclitaxel plus carboplatin induction followed by nanoparticle albumin-bound paclitaxel maintenance in squamous non-small-cell lung cancer (ABOUND.sqm): a phase III randomized clinical trial.","volume":"22","author":"Spigel","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.18.02178","article-title":"Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline.","volume":"37","author":"Shroff","year":"2019","journal-title":"J Clin Oncol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12885-017-3967-0","article-title":"Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: a prospective single center phase II study.","volume":"18","author":"Siebenh\u00fcner","year":"2018","journal-title":"BMC Cancer"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s12032-018-1115-6","article-title":"Gemcitabine-cisplatin (GC) as adjuvant chemotherapy in resected stage II and stage III gallbladder cancers (GBC): a potential way forward.","volume":"35","author":"Ostwal","year":"2018","journal-title":"Med Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:13:52Z","timestamp":1746324832000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":23,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035430","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]}}}